Compare KOF & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOF | GH |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | Mexico | United States |
| Employees | 90000 | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 20.6B |
| IPO Year | N/A | 2018 |
| Metric | KOF | GH |
|---|---|---|
| Price | $103.89 | $152.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $111.00 | ★ $119.79 |
| AVG Volume (30 Days) | 129.6K | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $7.55 | $33.30 |
| Revenue Next Year | $6.69 | $28.27 |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $80.23 | $40.36 |
| 52 Week High | $116.36 | $174.08 |
| Indicator | KOF | GH |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 52.74 |
| Support Level | $97.57 | $123.88 |
| Resistance Level | $109.16 | $174.08 |
| Average True Range (ATR) | 2.17 | 8.40 |
| MACD | -0.22 | -2.61 |
| Stochastic Oscillator | 30.11 | 23.33 |
Coca-Cola Femsa, a subsidiary of Femsa, is the largest franchise bottler of Coca-Cola in volume terms. The company purchases beverage concentrates and syrup from Coca-Cola, which it then processes and packages for distribution through modern trade, traditional trade, and the on-premises channel. Mexico and Brazil make up 80% of the total volume and sales, with the rest from other Central and South American countries, including Panama, Guatemala, Uruguay, and Argentina. Femsa and Coca-Cola hold 47% and 28% economic interests in Coca-Cola Femsa through nonpublicly traded A and D shares, respectively, while controlling 56% and 33% of the voting power.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.